Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors

FREMONT, Calif., March 16, 2020 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Onaiza Cadoret-Manier, an industry veteran with deep biopharmaceutical commercial experience, has joined the Company's Board of Directors. Ms. Cadoret-Manier replaces Annalisa Jenkins, who stepped down from the board effective March 12, 2020 in order to be closer and more involved with her Board responsibilities in Europe.

"We are pleased to welcome Onaiza to our board of directors," said Mike Raab, president and chief executive officer of Ardelyx. "Her wealth of experience, including commercialization and strategic planning for products at our stage, will be invaluable as we advance towards the potential launch and commercialization of tenapanor for the control of serum phosphorus in chronic kidney disease patients (CKD) on dialysis."

"With three successful Phase 3 trials for their lead therapeutic, tenapanor, this is an extremely exciting time for Ardelyx," said Ms. Cadoret-Mainer. "I believe tenapanor has the potential to change the landscape for the control of serum phosphorus– finally, a fresh approach to phosphate control for patients. I'm looking forward to serving on the board and helping to guide the company through its transformation into a commercial organization with potential approval of its first marketed drug."

Mike Raab added, "I want to thank Annalisa for her friendship, leadership and guidance over the past five years. She has been an extremely valuable member of the board of directors and it's been my pleasure to work with her."

Annalisa Jenkins joined the company's board of directors in 2015. Since joining the board, she has provided important contributions to help advance the company's clinical development programs with her broad range of industry experience.

Ms. Cadoret-Manier is an international commercialization and operations executive and life sciences industry veteran with over 30 years of experience driving growth for start-up and Fortune 500 companies. She has led and directed multiple new product launches with responsibility for product planning and commercialization through all phases of the product life cycle and across multiple therapeutic areas to heightened success in highly competitive markets. Ms. Cadoret-Manier currently serves as chief corporate development and commercial officer at Ionis Pharmaceuticals and previously was the chief commercial officer for Grail Biosciences, an early detection genomics company, where she developed the commercial strategy and business model. Prior to Grail, she was vice president of the respiratory franchise at Genentech, where she built and managed a team of more than 400 employees responsible for successfully commercializing medicines that generated approximately $3 billion in revenue. Ms. Cadoret-Manier also has held multiple senior management positions overseeing corporate strategy, alliances, and marketing and sales for numerous disease areas for Genentech, Pfizer and Amylin Pharmaceuticals. She has an MBA from the University of Chicago and a bachelor's degree in economics and accounting from City University of New York Queens College.

About Ardelyx, Inc.
Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing first-in-class medicines. Ardelyx's cardiorenal pipeline includes the Phase 3 development of tenapanor for the control of serum phosphorus in patients with CKD on dialysis, and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELA (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada.

Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including the potential for tenapanor to be approved for marketing by the FDA and commercialized for the control of serum phosphorus in chronic kidney disease patients on dialysis. Such forward-looking statements involve substantial risks and uncertainties that could cause the development of Ardelyx's product candidates or Ardelyx's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical development process, the uncertainties associated with the regulatory approval process, and uncertainties in the drug commercialization process. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx's annual report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2020, and its future current and periodic reports to be filed with the Securities and Exchange Commission.

SOURCE Ardelyx

Related Links

http://www.ardelyx.com